FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Peto bristles at Vytorin-cancer questions

Tools

Sir Richard Peto takes umbrage at the idea that he might skew a statistical analysis to benefit a drugmaker. The eminent Oxford statistician, as you know, recently weighed in on a study that seemed to link the Merck/Schering-Plough cholesterol med Vytorin with an increase in cancer cases and deaths. Peto concluded that the apparent risk was a statistical anomaly, a freak of chance.

Now, Peto is defending that conclusion against the opinions of other experts and questions from the U.S. Congress. In a letter to Reps. John Dingell and Bart Stupak, who are investigating the Vytorin controversy, Peto asserted that "any competent trial statistician" would agree with his analysis. Suggestions that he might bias his work in favor of Merck and Schering-Plough are absolutely wrong: They don't pay his salary and had no impact on his analysis of the trial data.

Apparently, Peto takes a dim view of the competency of the New England Journal of Medicine and its experts. Two NEJM editorials recently critiqued Peto's analysis, saying that an increased risk of cancer death in Vytorin patients can't be ruled out. Peto hasn't specifically addressed their conclusions--yet.

- read the Forbes story
- check out the Wall Street Journal Health Blog post

Related Articles:
Vytorin debate heats up ESC
Merck, Schering-Plough stocks take a dive
FDA probes Vytorin cancer risk
Letter tries to quell Vytorin worries
Analyst gloomy on Merck trends


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about drug safety   Schering-Plough   Vytorin   Congress   John Dingell   Bart Stupak   SEAS study   Richard Peto   New England Journal of Medicine   Merck